The Italian company has announced two major investments in Spain with the acquisition of three ophthalmic products on the Spanish market from the multinational company Novartis, and the acquisition of the Spanish company Soluciones Bioregenerativas SL.

Fidia, an Italian multinational pharmaceutical company, has announced the acquisition of three…
Fidia’s Hyaluronic Acid from fermentation has been recently granted the Certificate of Suitability…
Fidia farmaceutici today announced the positive preliminary results from an open-label, single-arm,…

Fidia Pharma Egypt is headquartered in Cairo, with a sales team of 45 people and is market leader of IAHA products

Fidia Farmaceutici announces the expansion of its affiliate network, with the recent opening of…

Unique formulation with a bioactive curcumin extract Bio-Curcumin Curcugreen™ (100% natural turmeric), glucosamine hydrochloride and chondroitin sulfate.

Fidia Farmaceutici is introducing CartiJoint™ FORTE, its first product in the dietary supplement…

First product in the regenerative medicine category

FLORHAM PARK, N.J.--(BUSINESS WIRE)-- Fidia, a world leader in the research, development, and…

The “ Sleep&Psyche” project dedicated to psychiatry specialists

Findings from recent studies have demonstrated the close relationship between disruption of the sleep-wake cycle and chronic conditions

Thanks to the contribution of Fidia Farmaceutici, the 2019 edition of the Sleep& Psyche Project…


Find out more about Fidia’s product portfolio:

Go to the website

Key Business Areas

Fidia operates in numerous therapeutic areas, providing specific, innovative treatments for commonly occurring pathologies with major socio-economic impact, namely:

- joint healthcare
- ophthalmology
- wound care
- dermatology
- neurology
- dermo-aesthetics